The impact of molecular profiling on cholangiocarcinoma clinical trials and experimental drugs

Qurat Ul Ain Riaz Sipra; Rachna Shroff

doi:10.1080/13543784.2021.1849139

The impact of molecular profiling on cholangiocarcinoma clinical trials and experimental drugs

Expert Opin Investig Drugs. 2021 Apr;30(4):281-284. doi: 10.1080/13543784.2021.1849139. Epub 2020 Nov 23.

Authors

Qurat Ul Ain Riaz Sipra¹, Rachna Shroff²

Affiliations

¹ Department of Medicine, University of Arizona, Tucson, AZ, USA.
² Department of Medicine, Division of Hematology/Oncology, University of Arizona, Tucson, AZ, USA.

PMID: 33228417
DOI: 10.1080/13543784.2021.1849139

No abstract available

Keywords: Cholangiocarcinoma; biliary tract cancer; extrahepatic cholangiocarcinoma; fibroblast growth factor receptor; genetics; genomic profiling; intrahepatic cholangiocarcinoma; isocitrate dehydrogenase; targeted therapies.

Publication types

Editorial

MeSH terms

Antineoplastic Agents / pharmacology*
Bile Duct Neoplasms / drug therapy*
Bile Duct Neoplasms / pathology
Cholangiocarcinoma / drug therapy*
Cholangiocarcinoma / pathology
Drugs, Investigational / pharmacology
Humans
Molecular Targeted Therapy

Substances

Antineoplastic Agents
Drugs, Investigational